Aug. 19 at 8:27 AM
$OTLK $GME $AMC APES, THIS ONE MAY BE WORTH A LOOK 👀
Current price: ~
$0.73
The fundamentals:
🟢 FDA-approved LYTENAVA
🟢 ~
$51.1M net financing for commercialization
🟢 U.S. launch targeted before year-end 2026
🟢 Launch inventory already built
🟢 EU units +46% QoQ
🟢
$50–75M first-year U.S. net revenue despite a progressive launch ramp
🟢 Base Case: >
$500M annual U.S. sales before 2030
And then there’s the trading activity:
🔥 Multiple recent sessions with exceptionally high volume, including 100M+ share days
20.77M off-exchange short volume / 64.92% short-volume ratio
Reported shares available to short: 7.4M → 700K
That’s roughly a 90% reduction in reported borrow availability.
None of this guarantees a squeeze.
But this setup is worth putting on the radar. 👀
$OTLK
